JP2007537258A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007537258A5 JP2007537258A5 JP2007513239A JP2007513239A JP2007537258A5 JP 2007537258 A5 JP2007537258 A5 JP 2007537258A5 JP 2007513239 A JP2007513239 A JP 2007513239A JP 2007513239 A JP2007513239 A JP 2007513239A JP 2007537258 A5 JP2007537258 A5 JP 2007537258A5
- Authority
- JP
- Japan
- Prior art keywords
- component
- amount
- volume
- cremophor
- propylene glycol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 27
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical group CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 12
- 239000008389 polyethoxylated castor oil Substances 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 10
- 239000000203 mixture Substances 0.000 claims 10
- 239000003186 pharmaceutical solution Substances 0.000 claims 10
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims 9
- QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical group C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 claims 9
- 239000003981 vehicle Substances 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 claims 7
- 229950007866 tanespimycin Drugs 0.000 claims 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 6
- 229920002556 Polyethylene Glycol 300 Polymers 0.000 claims 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 2
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 2
- 238000003756 stirring Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
Claims (16)
- (i)約40容量％〜約60容量％の量の、エタノールである第一成分、(ii)約15容量％〜約50容量％の量の、ポリエトキシル化ヒマシ油である第二成分、及び(iii)約０容量％〜約35容量％の量の、プロピレングリコール、PEG300、PEG400、グリセロール、及びこれらの組み合わせからなる群から選ばれる第三成分を含むビヒクルに溶解された15mg/mLまでの量の17-AAGを含むことを特徴とする医薬溶液製剤。
- 第二成分がクレモフォーELである、請求項１記載の医薬溶液製剤。
- 第三成分がプロピレングリコールである、請求項１記載の医薬溶液製剤。
- ビヒクルが約45容量％〜約50容量％の量の第一成分、約20容量％〜約30容量％の量の第二成分、及び約20容量％〜約30容量％の量の第三成分を含む、請求項１記載の医薬溶液製剤。
- 第二成分がクレモフォーELであり、かつ第三成分がプロピレングリコールである、請求項４記載の医薬溶液製剤。
- ビヒクルが約50容量％のエタノール、約20容量％のクレモフォーEL、及び約30容量％のプロピレングリコールを含む、請求項１記載の医薬溶液製剤。
- ビヒクルが約45容量％のエタノール、約28容量％のクレモフォーEL、及び約27容量％のプロピレングリコールを含む、請求項４記載の医薬溶液製剤。
- 第三成分が不在である、請求項１記載の医薬溶液製剤。
- (a) 或る量の17-AAGを容器中に用意する工程、
(b) 工程(a)の17-AAGを(i)約40容量％〜約60容量％の量の、エタノールである第一成分、(ii)約15容量％〜約50容量％の量の、ポリエトキシル化ヒマシ油である第二成分、及び(iii)約０容量％〜約35容量％の量の、プロピレングリコール、PEG300、PEG400、グリセロール、及びこれらの組み合わせからなる群から選ばれる第三成分を含む或る量のビヒクルと合わせる工程、
(c) 17-AAGが実質的に溶解されるまで工程(c)からの組み合わせを撹拌する工程、及び (d) 必要により工程(c)からの撹拌組み合わせを濾過して17-AAGを含む医薬溶液製剤を生成する工程
を含み、
工程(a)の17-AAGの量及び工程(b)のビヒクルの量は医薬溶液製剤中の17-AAGの濃度が15mg/mLまでであるような量であることを特徴とする、17-AAGを含む医薬溶液製剤の調製方法。 - 第二成分がクレモフォーELである、請求項９記載の方法。
- 第三成分がプロピレングリコールである、請求項９記載の方法。
- ビヒクルが約45容量％〜約50容量％の量の第一成分、約20容量％〜約30容量％の量の第二成分、及び約20容量％〜約30容量％の量の第三成分を含む、請求項９記載の方法。
- 第二成分がクレモフォーELであり、かつ第三成分がクレモフォーELである、請求項１１記載の方法。
- ビヒクルが約50容量％のエタノール、約20容量％のクレモフォーEL、及び約30容量％のプロピレングリコールを含む、請求項９記載の方法。
- ビヒクルが約45容量％のエタノール、約28容量％のクレモフォーEL、及び約27容量％のプロピレングリコールを含む、請求項９記載の方法。
- 第三成分が不在である、請求項９記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57021504P | 2004-05-11 | 2004-05-11 | |
| US11/123,570 US20050256097A1 (en) | 2004-05-11 | 2005-05-05 | Pharmaceutical solution formulations containing 17-AAG |
| PCT/US2005/016010 WO2005110398A2 (en) | 2004-05-11 | 2005-05-06 | Pharmaceutical solution formulations containing 17-aag |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007537258A JP2007537258A (ja) | 2007-12-20 |
| JP2007537258A5 true JP2007537258A5 (ja) | 2008-06-19 |
Family
ID=35310196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513239A Abandoned JP2007537258A (ja) | 2004-05-11 | 2005-05-06 | １７−ａａｇを含む医薬溶液製剤 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20050256097A1 (ja) |
| EP (1) | EP1744743A2 (ja) |
| JP (1) | JP2007537258A (ja) |
| AU (1) | AU2005244115A1 (ja) |
| BR (1) | BRPI0511036A (ja) |
| CA (1) | CA2565583A1 (ja) |
| IL (1) | IL178689A0 (ja) |
| MX (1) | MXPA06012935A (ja) |
| RU (1) | RU2382643C2 (ja) |
| WO (1) | WO2005110398A2 (ja) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090197852A9 (en) * | 2001-08-06 | 2009-08-06 | Johnson Robert G Jr | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |
| NZ550320A (en) | 2004-04-15 | 2010-02-26 | Chiasma Inc | Compositions capable of facilitating penetration across a biological barrier |
| KR20080007642A (ko) * | 2005-04-29 | 2008-01-22 | 코산 바이오사이언시즈, 인코포레이티드 | 프로테아좀 억제제와 함께 17-ａａｇ 또는 17-ａｇ 또는 둘중 하나의 전구약물을 사용하여 다발성 골수종을 치료하는방법 |
| AU2006242540A1 (en) * | 2005-04-29 | 2006-11-09 | Kosan Biosciences Incorporated | Method of treating multiple myeloma using 17-AAG of 17-AG of a prodrug of either |
| US20090042847A1 (en) * | 2005-11-23 | 2009-02-12 | Kosan Biosciences Incorporated | 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations |
| US7648976B2 (en) * | 2005-11-23 | 2010-01-19 | Bristol-Myers Squibb Company | 17-allylamino-17-demethoxygeldanamycin polymorphs and formulations |
| US20070167422A1 (en) * | 2006-01-18 | 2007-07-19 | Yu Kwok S | Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin |
| WO2008044041A1 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP2073807A1 (en) | 2006-10-12 | 2009-07-01 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008055386A1 (fr) * | 2006-11-10 | 2008-05-15 | Shenzhen Shengeryimei Biotech Co., Ltd. | Composition pharmaceutique hydrosoluble pour injection de 17-allyl amino-17-déméthoxy geldanamycine (17-aag) |
| PE20081506A1 (es) * | 2006-12-12 | 2008-12-09 | Infinity Discovery Inc | Formulaciones de ansamicina |
| WO2008094438A1 (en) | 2007-01-26 | 2008-08-07 | Kosan Biosciences Incorporated | Macrolactams by engineered biosynthesis |
| WO2009009067A2 (en) * | 2007-07-09 | 2009-01-15 | Kwon Glen S | Micelle encapsulation of theropeutic agents |
| EA019867B1 (ru) * | 2007-10-08 | 2014-06-30 | Фовея Фармасьютикалс | Водные офтальмологические препараты |
| US20090258869A1 (en) * | 2008-02-08 | 2009-10-15 | The Regents Of The University Of California | Methods and compounds for treatment or prevention of substance-related disorders |
| BRPI0918652B1 (pt) | 2008-09-17 | 2021-10-19 | Chiasma, Inc. | Composição farmacêutica compreendendo um meio hidrofóbico e uma forma sólida que compreende polipeptídeo e sal de ácido graxo de cadeia média, processo de produção da mesma e forma de dosagem oral |
| EP2480207B1 (en) | 2009-09-25 | 2016-11-09 | Wisconsin Alumni Research Foundation | Micelle encapsulation of therapeutic agents |
| RU2529800C2 (ru) * | 2010-03-18 | 2014-09-27 | ИННОФАРМА, Инк. | Стабильные составы бортезомиба |
| US8945627B2 (en) | 2011-05-05 | 2015-02-03 | Wisconsin Alumni Research Foundation | Micelles for the solubilization of gossypol |
| US10682415B2 (en) | 2013-07-22 | 2020-06-16 | Wisconsin Alumni Research Foundation | Thermogel formulation for combination drug delivery |
| US10898582B2 (en) | 2014-12-11 | 2021-01-26 | University Of Utah Research Foundation | Bi-functional allosteric protein-drug molecules for targeted therapy |
| MA41462A (fr) | 2015-02-03 | 2021-05-12 | Chiasma Inc | Méthode de traitement de maladies |
| JP2018008922A (ja) * | 2015-08-04 | 2018-01-18 | わかもと製薬株式会社 | ステロイド白内障の予防及び治療 |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US553153A (en) * | 1896-01-14 | Type-writing machine | ||
| US4261989A (en) * | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| US6262022B1 (en) * | 1992-06-25 | 2001-07-17 | Novartis Ag | Pharmaceutical compositions containing cyclosporin as the active agent |
| US5932556A (en) * | 1995-09-17 | 1999-08-03 | Tam; Robert C | Methods and compositions for regulation of CD28 expression |
| ES2384551T3 (es) * | 1997-03-05 | 2012-07-06 | Sugen, Inc. | Formulaciones para agentes farmacéuticos hidrófobos |
| US20030044434A1 (en) * | 1997-07-29 | 2003-03-06 | Ping Gao | Self-emulsifying formulation for lipophilic compounds |
| US6121323A (en) * | 1997-12-03 | 2000-09-19 | 3M Innovative Properties Company | Bishydroxyureas |
| US5925776A (en) * | 1997-12-24 | 1999-07-20 | Schein Pharmacetical, Inc. | Polyethoxylated castor oil, process of making the same and formulations thereof |
| US6682758B1 (en) * | 1998-12-22 | 2004-01-27 | The United States Of America As Represented By The Department Of Health And Human Services | Water-insoluble drug delivery system |
| TW471968B (en) * | 1999-08-25 | 2002-01-11 | Committee On Chinese Medicine | Solamargine pharmaceutical composition for killing cancer cells |
| US20020037855A1 (en) * | 2000-05-05 | 2002-03-28 | Fritz Stanislaus | Stabilized medicament containing cysteinyl derivatives |
| CA2417495C (en) * | 2000-07-28 | 2013-04-30 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
| WO2002036110A2 (en) * | 2000-10-31 | 2002-05-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Oral self-emulsifying formulations of pyranone protease inhibitors |
| US7025992B2 (en) * | 2001-02-14 | 2006-04-11 | Gw Pharma Limited | Pharmaceutical formulations |
| ES2268068T3 (es) * | 2001-03-30 | 2007-03-16 | The Usa, Represented By The Secretary, Dept. Of Health And Human Services National Institutes Health | Derivado de geldanamicina util para el tratamiento del cancer. |
| WO2002092076A1 (en) * | 2001-05-16 | 2002-11-21 | Cytovia, Inc. | Substituted coumarins and quinolines as caspases activators |
| US6962944B2 (en) * | 2001-07-31 | 2005-11-08 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
| US6872715B2 (en) * | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
| US6653319B1 (en) * | 2001-08-10 | 2003-11-25 | University Of Kentucky Research Foundation | Pharmaceutical formulation for poorly water soluble camptothecin analogues |
| US8071133B2 (en) * | 2001-08-20 | 2011-12-06 | Stiefel Laboratories, Inc. | Oral dosage forms of water insoluble drugs and methods of making the same |
| WO2003032949A1 (en) * | 2001-10-19 | 2003-04-24 | Isotechnika Inc. | Novel cyclosporin analog microemulsion preconcentrates |
| NZ533062A (en) * | 2001-12-19 | 2006-03-31 | Alza Corp | Formulation and dosage form for the controlled delivery of therapeutic agents |
| AU2002359793B2 (en) * | 2001-12-19 | 2007-06-14 | Alza Corporation | Formulation and dosage form for increasing oral bioavailability of hydrophilic macromolecules |
| US6803046B2 (en) * | 2002-08-16 | 2004-10-12 | Bracco International B.V. | Sincalide formulations |
| US7649006B2 (en) * | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
-
2005
- 2005-05-05 US US11/123,570 patent/US20050256097A1/en not_active Abandoned
- 2005-05-06 RU RU2006143666/15A patent/RU2382643C2/ru not_active IP Right Cessation
- 2005-05-06 EP EP05779076A patent/EP1744743A2/en not_active Withdrawn
- 2005-05-06 BR BRPI0511036-0A patent/BRPI0511036A/pt not_active IP Right Cessation
- 2005-05-06 AU AU2005244115A patent/AU2005244115A1/en not_active Abandoned
- 2005-05-06 JP JP2007513239A patent/JP2007537258A/ja not_active Abandoned
- 2005-05-06 CA CA002565583A patent/CA2565583A1/en not_active Abandoned
- 2005-05-06 WO PCT/US2005/016010 patent/WO2005110398A2/en active Application Filing
- 2005-05-06 MX MXPA06012935A patent/MXPA06012935A/es active IP Right Grant
-
2006
- 2006-10-17 IL IL178689A patent/IL178689A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007537258A5 (ja) | ||
| RU2006143666A (ru) | Фармацевтические композиции в виде раствора, содержащие 17-aag | |
| JP2008523153A5 (ja) | ||
| CN1612737A (zh) | 铂衍生物药物制剂 | |
| CN102427803A (zh) | 亲水性药物之自微乳化医药组合物及其制备 | |
| JP2011523620A (ja) | タキサン誘導体を含有する、安定性が改良された凍結乾燥医薬組成物、及びその製法 | |
| JP2014129360A5 (ja) | ||
| RU2015137145A (ru) | Новые жидкие композиции с повышенной стабильностью | |
| AU2011248449B2 (en) | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same | |
| JP2003535893A5 (ja) | ||
| CN104507467B (zh) | 含紫杉烷系活性成分的液体组合物、其制造方法及液体制剂 | |
| RS52657B (en) | PACKAGING SYSTEM FOR PHARMACEUTICAL MIXTURES AND INTRAVEL APPLICATION KIT | |
| JP2010280739A (ja) | ビノレルビンを含むソフトカプセルのための経口製薬組成物及び治療方法 | |
| WO2014055426A1 (en) | Non-aqueous taxane nanodispersion formulations and methods of using the same | |
| CN106068122A (zh) | 二丁基羟基甲苯的稳定化方法 | |
| CN106132416A (zh) | 注射液制剂及其制造方法 | |
| RU2016103764A (ru) | Стабилизированные фармацевтические лекарственные формы, содержащие атрасентан | |
| Carr et al. | Triamterene nephrolithiasis: renewed attention is warranted | |
| WO2008077772A3 (en) | Combination of a retinoid and a platinum anticancer agent | |
| MX2007006926A (es) | Formulaciones inyectables o administrables por via oral de derivados de azetidina. | |
| JP5176352B2 (ja) | ユビデカレノン含有内服用組成物 | |
| JP2007332094A (ja) | アスコルビン酸のグリセリン溶液の製造方法及びアスコルビン酸のグリセリン溶液並びにアスコルビン酸のグリセリン溶液からなる化粧料素材。 | |
| JP2013194009A (ja) | ドセタキセル製剤 | |
| JP3748912B2 (ja) | オーレオバシジン類の高濃度溶液製剤 | |
| JPS62501075A (ja) | 軟ゼラチンカプセル及びその製造方法 |